← back to search

James C. Mulloy

University of Cincinnati Medical Center ·
Area of research
Hematology · Molecular Biology
Research interest
Research interests include Acute Myeloid Leukemia Research, Protein Degradation and Inhibitors, Hematopoietic Stem Cell Transplantation, and Acute Lymphoblastic Leukemia research.
h-index
58
citations
15,034
works
221
NIH funding
primary concept
Biology
email

Recent publications

ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Cancer Discovery 2025cited by 5position: middledoi
DDX6 undergoes phase separation to modulate metabolic plasticity and chemoresistance
Nature Communications 2025cited by 1position: middledoi
YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies
Cell 2024cited by 61position: middledoi
METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism
Cell stem cell 2023cited by 152position: middledoi
TET2-mediated mRNA demethylation regulates leukemia stem cell homing and self-renewal
Cell stem cell 2023cited by 104position: middledoi
The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia
Cancer Cell 2022cited by 300position: middledoi
Epigenetic regulator genes direct lineage switching in  <i>MLL/AF4</i> leukemia
Blood 2022cited by 67position: middledoi
Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia
Science Translational Medicine 2022cited by 46position: middledoi
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion
Cancer Cell 2020cited by 760position: middledoi
Asymmetrically Segregated Mitochondria Provide Cellular Memory of Hematopoietic Stem Cell Replicative History and Drive HSC Attrition
Cell stem cell 2020cited by 210position: middledoi
Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia
Cancer Cell 2019cited by 854position: middledoi
R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling
Cell 2017cited by 1,179position: middledoi
METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification
Cell stem cell 2017cited by 1,004position: middledoi
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia
Nature Medicine 2017cited by 102position: middledoi
Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia
Nature Communications 2017cited by 67position: middledoi
The full transforming capacity of MLL-Af4 is interlinked with lymphoid lineage commitment
Blood 2017cited by 31position: lastdoi
Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia
Cancer Cell 2016cited by 126position: middledoi
The AS‐RBM15 lncRNA enhances RBM15 protein translation during megakaryocyte differentiation
EMBO Reports 2016cited by 96position: middledoi
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199
Cell Reports 2015cited by 153position: middledoi
Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia
Proceedings of the National Academy of Sciences 2015cited by 111position: middledoi
UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO
Leukemia 2015cited by 65position: lastdoi
Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal
Blood 2014cited by 31position: middledoi
<i>TET1</i> plays an essential oncogenic role in <i>MLL</i> -rearranged leukemia
Proceedings of the National Academy of Sciences 2013cited by 221position: middledoi
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
Journal of Clinical Investigation 2013cited by 219position: middledoi
miR-9 is an essential oncogenic microRNA specifically overexpressed in <i>mixed lineage leukemia</i> –rearranged leukemia
Proceedings of the National Academy of Sciences 2013cited by 114position: middledoi
Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity
Journal of Clinical Investigation 2013cited by 75position: middledoi
miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia
Nature Communications 2012cited by 166position: middledoi
miR-495 is a tumor-suppressor microRNA down-regulated in <i>MLL</i> -rearranged leukemia
Proceedings of the National Academy of Sciences 2012cited by 106position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Mark Wunderlich · University of Cincinnati7 papers (2012–2025)Jianjun Chen · City Of Hope National Medical Center5 papers (2012–2025)Shan Lin · Broad Institute4 papers (2015–2017) · 3 papers (2013–2020)Roger Luo · Entegris (United States)2 papers (2016–2017)Gia-Ming Hong · University of Chicago2 papers (2012–2013)Janet D. Rowley · University of East London2 papers (2012–2013)Sandeep Gurbuxani · University of Chicago2 papers (2012–2013)Salam A. Assi · University of Birmingham2 papers (2015–2016)Zejuan Li · Houston Methodist2 papers (2012–2013)Colles Price · Mochida Pharmaceutical (Japan)2 papers (2012–2013)Mahesh Shrestha · Emory University2 papers (2015–2017)Hao Huang · Nanjing Forestry University2 papers (2012–2013)Michael J. Thirman · University of Chicago Medical Center2 papers (2016–2017)Chunjiang He · Huazhong Agricultural University2 papers (2012–2013)Rejani B. Kunjamma · Northwestern University2 papers (2012–2013)Anetta Ptasinska · University of Birmingham2 papers (2015–2016)Constanze Bonifer · University of Birmingham2 papers (2015–2016)Michelle M. Le Beau · Cancer Prevention and Research Institute of Texas2 papers (2012–2013)José A. Cancelas · Harvard University2 papers (2013–2017)